BrightStar Wisconsin Foundation announced recently that it has invested in Stem Pharm, Inc. Financial terms were not disclosed.

As previously reported, the biotech company focuses on creating adult stem cell-derived neural organoids to evaluate drug treatments for neural diseases such as Alzheimer’s, Parkinson’s, ALS and brain cancers such as glioblastoma multiforme (GBM).

Stem Pharm was selected for Illumina Accelerator in late 2019.